Gastric and oesophageal cancer trials in Japan

In Japan 55 Also abroad 1285

55 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Where
Chūō, Fukuoka, Kashiwa, Nagoya
Age
18 years and over
People
298 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00
Phase 1Taking people
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Where
Tokyo
Age
18 years and over
People
138 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00
Phase 1/2Taking people
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Where
Chūō, Nagoya, Yokohama
Age
18 years and over
People
60 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00
Phase 1Not yet taking people in Japan
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Shizuoka, Tokyo
Age
18 years and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
Phase 3Taking people
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Where
Akashi, Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Niigata, Osaka, Sapporo
Age
18 years and over
People
570 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Active, not recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Where
Akashi-shi, Chiba, Chuo Ku, Fukuoka, Hidaka-shi, Kashiwa, Kawasaki-shi, Kida-gun, Kitaadachi-gun Ina-machi, Kobe, Koto-ku, Maebashi, Matsuyama, Osaka, Sapporo, Sendai, Suita-shi, Sunto-gun, Yokohama
Age
18 years and over
People
500 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00
Phase 2/3Taking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Where
Chiba, Chuo Ku, Gifu, Kashiwa, Koto-ku, Kurashiki, Matsuyama, Minami-Ku, Fukuoka, Nagaizumi-cho,Sunto-gun, Nagoya, Osaka, Sendai, Suita, Takatsuki, Yokohama
Age
18 years and over
People
690 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Not yet taking people in Japan
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Where
Chiba, Kyoto, Osaka
Age
18 years and over
People
421 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00
Phase 1Not yet taking people in Japan
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Chiba, Kyoto
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 2Taking people
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Where
Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka, Suita-shi, Yokohama
Age
18 years and over
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00
Phase 2Taking people
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Where
Kashiwa
Age
18 years and over
People
26
Run by
National Cancer Center Hospital East
See details and how to joinNCT07018570
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Where
Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya, Osaka, Ōsaka-sayama, Saitama, Sapporo, Shinagawa-Ku, Shinjuku-ku, Suita-shi, Sunto-gun, Yokohama
Age
18 years and over
People
510 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00
Phase 1/2Taking people
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Where
Chuo Ku, Koto-ku
Age
18 years and over
People
392 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00
Phase 2Taking people
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Where
Chūōku, Osaka, Takatsukishi, Yokohama
Age
18 years and over
People
30
Run by
BeOne Medicines
See details and how to joinNCT07733180
Phase 2Taking people
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Where
Saitama, Tokyo, Yokohama
Age
18 years and over
People
29
Run by
National Cancer Center, Japan
See details and how to joinNCT07872722
Phase 3Taking people
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Where
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi, Kitaadachi-gun, Kita-gun, Kōtoku, Matsuyama, Niigata, Osaka, Osakasayama-shi, Ota-shi, Sakaishi, Sendai, Shiwa-gun, Suita-shi, Sunto-gun, Toyoake-shi, Yokohama
Age
18 years and over
People
840 worldwide
Run by
AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00
Phase 3Taking people
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Where
Bunkyō City, Chūōku, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku, Kurashiki-shi, Nagoya, Niigata, Osaka, Ota-shi, Sagamihara-shi, Sakai, Sendai, Shimotsuke-shi, Sunto-gun, Yokohama
Age
18 years and over
People
2,130 worldwide
Run by
AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 3Taking people
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Where
Bunkyoku, Hamamatsushi, Kitaadachigun, Kitakyushu, Matsuyama, SakaiShi, Sapporo, SumidaKu, Takatsukishi, Utsunomiya
Age
18 years and over
People
351 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00
Phase 2/3Taking people
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Where
Nagoya
Age
18 years and over
People
840 worldwide
Run by
Pfizer
See details and how to joinNCT07392892 · EU 2025-524717-86-00